Revised SPCs: Cosentyx (secukinumab) 150 mg solution for injection in pre-filled and syringe

SPCs revised to include headache, nausea and fatigue as common (≥ 1/100 to < 1/10) undesirable effects of treatment.

Source:

electronic Medicines compendium